+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

L

Actively Recruiting

Healthy Volunteer

Researchers are studying the persistence of immune response to the NmCV-5 vaccine, a pentavalent meningococcal ACYWX conjugate vaccine, in participants aged 2 to 29 years from Mali and The Gambia. The goal is to understand how long the antibody protection lasts more than five years after a single dose vaccination and whether a booster dose might be needed in this population. This observational long-term follow-up study involves contacting 1800 former participants from an earlier study by phone, followed by an in-person visit for a randomly selected subset of 450 participants. The study focuses on evaluating antibody levels against meningococcal serogroups A, C, Y, W, and X more than five years post-vaccination, measuring geometric mean titers and percentages of participants with specific antibody titers. Participants will be involved in a telephone interview and a clinical visit for blood sampling to assess antibody levels. Researchers will measure immune response persistence using serum bactericidal antibody titers. The study will monitor these immune markers to help determine the duration of vaccine-induced protection. Participation will last beyond five years after the initial vaccination, with safety and compliance monitored throughout.

Age: 7Years - 36YearsAll Genders
2 locations
R

Actively Recruiting

This registry collects detailed information about children diagnosed with cancer who are treated in pediatric oncology units affiliated with the French African Oncology Group in French-speaking Africa. Its goal is to gather data on patient numbers, cancer stage, treatments received, and outcomes to support better planning and delivery of pediatric oncology care in the region. The registry aims to provide valuable insights for local and national health authorities to improve pediatric cancer programs. Children and adolescents under 18 years old who present at participating pediatric oncology units and have any type of cancer are included in this observational registry. Data collected includes demographic information, socioeconomic status, clinical details, treatment status, vital status, treatment abandonment, and loss to follow-up. The information is entered online using the REDCap system and securely stored by the IT department at Gustave ROUSSY in Paris. Participants information is gathered continuously during their treatment and follow-up at the hospital units. The main measures tracked include the number of children suspected of having cancer within 12-month periods, their vital status, illness status, and treatment status. This ongoing data collection helps monitor outcomes and supports healthcare planning. Participation involves no experimental treatment and is focused on data recording and observation over time.

Age: 1Day - 18YearsAll Genders
14 locations
S

Actively Recruiting

Healthy Volunteer

Malaria caused by Plasmodium falciparum remains a serious global health problem, particularly affecting pregnant women and young children. This research aims to understand the immune and parasite factors linked to infection and disease in these groups. The study focuses on how pregnancy malaria leads to complications like low birth weight, anemia, and hypertension, and how early life exposure influences the risk of severe childhood malaria. Researchers hypothesize that parasites causing severe childhood malaria might have unique characteristics. The study is a long-term observational cohort conducted in Mali, involving up to 2000 pregnant women and their infants, 2000 children aged 0-3 years followed to age 5, as well as up to 3000 febrile children up to 10 years old. Additionally, 500 pregnant women are enrolled for a case-control study on pregnancy malaria and preeclampsia. About 1000 children from the original birth cohort are re-enrolled and followed for up to 10 years into adolescence and early adulthood. Participants receive clinical evaluations and blood sampling at various intervals throughout the study. Participants undergo regular clinical, parasitologic, and immune system assessments, with blood samples collected periodically. Hospitalized and non-hospitalized febrile children also provide acute and recovery samples. Researchers analyze these data to identify factors linked to malaria infection and disease outcomes in pregnant women and children. The study includes long-term follow-up of children into early adulthood to understand disease susceptibility over time.

Age: 1Day - 45YearsAll Genders
2 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effectiveness and real-life impact of a new way to deliver the R21 malaria vaccine combined with seasonal malaria chemoprevention SMC in children living in areas with highly seasonal malaria transmission in Burkina Faso and Mali. This Phase 4, two-arm cluster-randomized trial compares two vaccination approaches in children within defined health center areas, measuring clinical malaria cases, vaccine coverage, acceptability, feasibility, and cost-effectiveness. Children in the control group will receive the R21 vaccine through routine EPI vaccination either year-round for ages 5 to 36 months in Burkina Faso or as an annual campaign before malaria season and SMC delivery in Mali. The intervention group will receive a three-dose primary vaccine series aligned with SMC distribution during an annual campaign, covering children aged 3 to 59 months. These approaches aim to assess different delivery strategies of the R21Matrix-M vaccine alongside SMC. Participants will be monitored through routine malaria surveillance to track clinical malaria incidence. Cross-sectional surveys will check for malaria parasites in the community. Researchers will also assess vaccine coverage, acceptability, feasibility, adverse events, stakeholder perceptions, behavioral factors affecting vaccine uptake, and cost-effectiveness over periods ranging from 4 months up to 36 months after enrollment. The primary outcome is malaria incidence in children aged 5 to 36 months over 12 months from enrollment.

Age: 3Months - 59MonthsAll GendersPhase 4
2 locations
L

Actively Recruiting

Healthy Volunteer

Malaria is a serious disease caused by parasites spread through mosquito bites, which can be fatal if untreated. Pregnant women, especially those aged 15 to 25, are at higher risk of malaria infection, which can lead to complications like low birth weight and maternal anemia. Researchers are investigating vaccine candidates aimed at preventing pregnancy malaria by studying how antibodies work against the parasite in laboratory tests. This research involves recruiting up to 2492 pregnant women who are malaria-infected from health centers in Mali, West Africa. Blood samples from these participants will be used to test the functional activity of antibodies raised against malaria vaccine candidates in lab assays. The study compares these antibodies to naturally acquired ones to assess their potential in blocking the parasites ability to bind to the placenta. Participants will provide blood samples and may undergo physical exams. Those diagnosed with malaria or anemia will receive treatment. Researchers will measure how well antibodies block the parasites binding to the placental receptor over about one year. The study includes consent for use of samples in future research, and participation may last through the pregnancy period, with ongoing health monitoring and data collection.

Age: 15Years - 25YearsFEMALE
1 location
S

Actively Recruiting

Healthy Volunteer

Researchers are studying allergic diseases such as asthma and atopic dermatitis in people living in Mali to understand factors that may influence these conditions. This observational case-control study compares people with allergic diseases to healthy individuals, examining differences in biological and environmental factors that might be linked to allergic diseases. The goal is to identify clues about the causes and contributing elements of these diseases by analyzing various samples and health information. Participants include people diagnosed with atopic diseases and age- and sex-matched healthy controls. All participants undergo clinical evaluations and provide skin swabs, nasal swabs, induced sputum when possible, blood samples, stool samples, and drinking water samples. They also complete questionnaires about environmental exposures. Pulmonary function tests and skin electrical impedance measurements are performed to assess respiratory and skin function. Environmental samples from the community and participant homes are collected to evaluate pollution exposure. During the study, participants provide biological and environmental samples and complete health questionnaires. Researchers analyze the microbiome diversity in different body sites and measure environmental pollutants and immune markers. The main outcome is the difference in gut microbiome between allergic patients and healthy controls within 28 days after screening. Secondary measures include skin and nasal microbiome analysis, pollutant levels, and immune cell counts. The study involves thorough assessments focused on understanding allergic diseases and their environmental associations.

Age: 3Years +All Genders
2 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, immune response, and protective effects of the PfSPZ-LARC2 Vaccine in healthy adult women of childbearing potential WOCBP aged 18 to 38 years in Mali. This randomized, double-blind, placebo-controlled study involves women who agree to use birth control during vaccination and plan to become pregnant within the next year. The study aims to assess vaccine effects over two years, including during malaria transmission seasons, and closely monitors pregnancy outcomes and infant health. Participants are randomly assigned to one of two groups one receives three doses of the PfSPZ-LARC2 Vaccine via direct venous inoculation at days 1, 6, and 29, while the other group receives placebo injections on the same schedule. All participants receive antimalarial treatment with artemetherlumefantrine about 2 to 4 weeks before the first vaccine dose and about 2 weeks before the third dose. Follow-up includes monitoring for safety, immune responses, and malaria infections during rainy and dry seasons over two years. Pregnant participants and their infants are followed for safety and malaria outcomes through pregnancy and for at least one year after delivery. During the study, participants undergo blood tests, pregnancy monitoring, and assessments for malaria infection and clinical cases. Safety is tracked through recorded adverse events, including injection site reactions and serious events, as well as laboratory tests. Pregnant women and newborns are assessed for obstetric and neonatal health outcomes such as miscarriage, birth weight, and congenital abnormalities. The study collects data on time to first malaria infection, clinical malaria episodes, pregnancy outcomes, and infant infections to understand vaccine impact and safety over the extended follow-up period.

Age: 18Years - 38YearsFEMALEPhase 2
1 location
T

Actively Recruiting

This research aims to improve treatment for children with Burkitts Lymphoma across at least 14 Sub Saharan countries, some new to this type of study. It focuses on earlier evaluation of children with stage I and II disease and earlier assessment of treatment response to decide if changes are needed. It also intends to intensify treatment for children with stage IV disease. Starting in 2026, the study will assess adding rituximab to current treatments and compare results with earlier implementations in two specific centers. The study involves observing the ability of treatment centers to follow the established GFA LMB2019 protocol for Burkitts Lymphoma. In two units, an amendment adds four rituximab injections during induction treatment, given on day 1 and day 6 of each induction cycle, depending on the risk group and treatment regimen. Other centers will continue using the original GFA LMB2019 treatment protocol without rituximab. Participants will be monitored over five years to evaluate the number of cases diagnosed with local disease and by stage, the treatments given, follow-up after treatment, and relapse rates. The study will also assess how well therapeutic recommendations are applied. This long-term observation helps understand treatment outcomes and the impact of adding rituximab in selected centers.

Age: 0 - 18YearsAll Genders
7 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of antimalarial drugs for treating uncomplicated malaria during the first trimester of pregnancy, a critical period for both mother and baby. The study compares the current standard treatment, artemether-lumefantrine AL, with newer antimalarials like pyronaridine-artesunate PA and dihydroartemisinin-piperaquine DP that have shown promise in earlier studies. The goal is to confirm if these newer drugs work as well as AL and are safe for pregnancy outcomes, while offering benefits such as simpler dosing and longer protection against new infections. The trial uses a Bayesian Adaptive Platform design that allows adding new treatments over time and stopping arms early if safety concerns arise. Pregnant women diagnosed with uncomplicated malaria in their first trimester are randomly assigned to receive AL twice daily for 3 days, or PA or DP once daily for 3 days with weight-based dosing. The study is open-label and conducted in multiple African countries where malaria is common. Participants will be monitored closely with daily visits for 4 days, weekly visits for 6 weeks, followed by monthly visits until delivery. Health and pregnancy outcomes will be tracked, and newborns followed for 6 months after birth. Safety data will be reviewed regularly by an independent monitoring board. The primary measure of success is the clinical and parasitological response at day 42. This research aims to expand safe treatment options for malaria in early pregnancy and improve health outcomes for mothers and babies in malaria-affected regions.

Age: 16Years +FEMALEPhase 3
3 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are conducting a Phase 1b, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and mosquitocidal activity of single oral doses of lotilaner in healthy adults living in Mali. This study aims to provide proof-of-concept data on lotilaners effects and behavior in the body when given to adults aged 18 to 55. The study involves three staggered groups of 25 participants each. Participants are randomized in a 41 ratio to receive either a single dose of lotilaner or placebo. The doses vary by cohort, including a low dose with a high-fat meal, a high dose in a fasted state, and a high dose with a high-fat meal. The dosing occurs on Day 1, and the next group starts only after safety and tolerability are reviewed for at least 8 days from the previous group. Blood samples will be collected regularly over about 6 months to assess safety, drug levels, and the bloods ability to kill mosquitoes. Participants will visit the clinical unit for follow-up visits according to the assessment schedule for approximately six months. During these visits, blood will be tested for safety and pharmacokinetic analyses. Mosquitocidal efficacy will be evaluated using mosquito membrane feeding assays on collected blood samples. The main outcome measured is the safety and tolerability of lotilaner from dosing through Day 169, along with various pharmacokinetic and mosquito survivorship assessments.

Age: 18Years - 55YearsAll GendersPhase 1
1 location

1-10 of 14

1